# IFNA14

## Overview
IFNA14 is a gene that encodes the protein interferon alpha 14, a member of the type I interferon family, which plays a pivotal role in the immune system's antiviral defense mechanisms. The protein interferon alpha 14 is categorized as a cytokine, which is involved in the activation of the JAK-STAT signaling pathway, leading to the transcription of interferon-stimulated genes (ISGs) that are crucial for antiviral responses (Karakoese2024IFNα). IFNA14 is located on chromosome 9p21, within a cluster of type I interferon genes, and its expression is regulated by transcription factors such as IRF-7 and CTCF, which influence its response to viral infections (Lin2000Selective; Feng2013Bioinformatics). The gene has been studied for its potential implications in various diseases, including severe COVID-19, asthma, and multiple sclerosis, although its specific clinical significance remains an active area of research (Miterski1999The; Badla2023Genetic; Chan2006Variation).

## Function
IFNA14 encodes interferon alpha 14, a member of the type I interferon family, which plays a crucial role in the immune response, particularly in antiviral defense. IFN-α14 is involved in the activation of the JAK-STAT signaling pathway upon binding to its receptor, composed of IFNAR1 and IFNAR2 subunits. This activation leads to the formation of the ISGF3 complex, which translocates to the nucleus to induce the transcription of numerous interferon-stimulated genes (ISGs) (Karakoese2024IFNα). IFN-α14 is noted for its strong antiviral activity, inducing a large number of ISGs compared to other subtypes, which includes the activation of both canonical and non-canonical signaling pathways, such as STAT1:STAT2 heterodimer signaling and STAT1:STAT1 homodimer activation of GAS elements (Karakoese2024IFNα).

In healthy human cells, IFN-α14 is primarily active in the cytoplasm and nucleus, where it modulates immune responses and inhibits viral replication. It has been shown to significantly increase the phosphorylation frequencies of signaling molecules such as STAT1, STAT3, and STAT5 in T and NK cells, suggesting a subtype-specific potency in stimulating immune responses (Karakoese2024IFNα). The protein's ability to induce a broader range of ISGs is correlated with its potent antiviral effects against viruses like HIV and HBV (Karakoese2024IFNα).

## Clinical Significance
Mutations and alterations in the IFNA14 gene have been implicated in several diseases and conditions. In the context of severe COVID-19, rare variants in IFNA14 have been identified in young Asian and Middle Eastern patients, suggesting a potential role in disease severity. These variants were associated with higher rates of ICU admission and mortality, although the associations did not reach statistical significance due to small sample sizes (Badla2023Genetic). 

The IFNA14 gene is also part of the type I interferon gene cluster on chromosome 9p21, which has been studied for its influence on susceptibility to asthma and atopy. Variations within this cluster, including IFNA14, may contribute to the risk of these conditions, although specific clinical significances of IFNA14 alone are not detailed (Chan2006Variation).

In multiple sclerosis (MS), IFNA14, along with other IFNA genes, has been considered a candidate for disease predisposition. While the study did not find a significant association with MS for IFNA14 specifically, it highlighted the complexity of genetic factors in MS and the potential involvement of IFNA genes (Miterski1999The). 

Overall, the clinical significance of IFNA14 mutations and expression alterations is an area of ongoing research, with implications for viral infections, autoimmune diseases, and inflammatory conditions.

## Interactions
IFNA14 interacts with the type I interferon receptor, which consists of the subunits IFNAR1 and IFNAR2. IFNA14 binds to IFNAR2 with higher affinity than to IFNAR1, forming a ternary complex that activates the JAK-STAT signaling pathway. This interaction leads to the induction of interferon-stimulated genes (ISGs) and is associated with strong antiviral activity against viruses such as HIV and HBV (Karakoese2024IFNα).

The IFNA14 promoter is specifically activated by the transcription factor IRF-7, which binds to PRDI-like sites on the promoter. This binding is crucial for the expression of IFNA14 in response to viral infections. IRF-7 does not associate with coactivators like CBP, p300, and PCAF in the same manner as IRF-3, indicating a unique regulatory mechanism for IFNA14 expression (Lin2000Selective).

CTCF, a transcriptional repressor, also plays a role in regulating IFNA14 expression by influencing the 3D structure of chromatin. CTCF binding sites in the promoter region of IFNA14 suggest a regulatory role, potentially involving the cohesin complex, which assists in forming chromatin loops that can block enhancer-promoter interactions (Feng2013Bioinformatics).


## References


[1. (Karakoese2024IFNα) Zehra Karakoese, Martha Ingola, Barbara Sitek, Ulf Dittmer, and Kathrin Sutter. Ifnα subtypes in hiv infection and immunity. Viruses, 16(3):364, February 2024. URL: http://dx.doi.org/10.3390/v16030364, doi:10.3390/v16030364. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/v16030364)

[2. (Miterski1999The) B Miterski, S Jaeckel, JT Epplen, D Pöhlau, and C Hardt. The interferon gene cluster: a candidate region for ms predisposition? Genes &amp; Immunity, 1(1):37–44, September 1999. URL: http://dx.doi.org/10.1038/sj.gene.6363634, doi:10.1038/sj.gene.6363634. This article has 19 citations.](https://doi.org/10.1038/sj.gene.6363634)

3. (Badla2023Genetic) Genetic determinants of severe COVID-19 in young Asian and Middle Eastern patients. This article has 4 citations.

[4. (Lin2000Selective) Rongtuan Lin, Pierre Génin, Yaël Mamane, and John Hiscott. Selective dna binding and association with the creb binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. Molecular and Cellular Biology, 20(17):6342–6353, September 2000. URL: http://dx.doi.org/10.1128/mcb.20.17.6342-6353.2000, doi:10.1128/mcb.20.17.6342-6353.2000. This article has 235 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.20.17.6342-6353.2000)

[5. (Feng2013Bioinformatics) Di Feng and Betsy J. Barnes. Bioinformatics analysis of the factors controlling type i ifn gene expression in autoimmune disease and virus-induced immunity. Frontiers in Immunology, 2013. URL: http://dx.doi.org/10.3389/fimmu.2013.00291, doi:10.3389/fimmu.2013.00291. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2013.00291)

[6. (Chan2006Variation) A Chan, D L Newman, A M Shon, D H Schneider, S Kuldanek, and C Ober. Variation in the type i interferon gene cluster on 9p21 influences susceptibility to asthma and atopy. Genes &amp; Immunity, 7(2):169–178, January 2006. URL: http://dx.doi.org/10.1038/sj.gene.6364287, doi:10.1038/sj.gene.6364287. This article has 16 citations.](https://doi.org/10.1038/sj.gene.6364287)